Post-marketing Surveillance (Special Use-results Surveillance) on Treatment With Alhemo

Inclusion Criteria: * Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). * The decision to initiate treatment with commercially available Alhemo has been made by the participant/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the participant in this study. * Male or female, age above or equal to 12 years at the time of signing informed consent. * Diagnosis with Haemophilia A (HA) or Haemophilia B (HB). * Participant who has never been exposed to concizumab or who starts treatment with concizumab within the past 12 weeks at registration. Exclusion Criteria: * Previous participation in this study. Participation is defined as having given informed consent in this study. * Treatment with any investigational drug within 30 days prior to baseline (the starting date of Alhemo treatment). * Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation. * A history of hypersensitivity to any ingredients of Alhemo.